High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients

• DOI: 10.1007/s12149-021-01602-x
• Publication Date: 2021-03-04T13:07:12Z
• Authors: Tadashi Watabe; Motohide Uemura; Fumihiko Soeda; Sadahiro Naka; Takeshi Ujike; Koji Hatano; Hidetaka Sasaki; Takashi Kamiya; Eku Shimosegawa; Hiroki Kato; Jens Cardinale; Ukihide Tateishi; Norio Nonomura; Frederik L. Giesel
• Keywords: Biochemical recurrence; Glutamate carboxypeptidase II; breakpoint cluster region; Bone scintigraphy

18F-labeled prostate-specific membrane antigen (PSMA) ligand, [18F]PSMA-1007, has the benefit of a higher synthetic yield and minimal excretion in urine. High detection efficacy was reported biochemical recurrence (BCR) prostate cancer after radical prostatectomy. Thus, we evaluated preliminary diagnostic utility [18F]PSMA-1007 PET patients with cancer, focusing on BCR which is not detected conventional imaging.We enrolled total 28 (age 51-79 years) cancer. defined as continuous increase PSA prostatectomy or radiation therapy without any apparent recurrent lesions imaging (CT bone scintigraphy). PSMA-PET scanning performed approximately 60 min intravenous injection (259 ± 37 MBq). images were for lesion well its relation to values location.Abnormal uptake, suspected be metastasis, 92.9% (26/28) BCR. The SUVmax 8.4 6.4 local recurrence, 11.5 11.8 pelvic lymph nodes (LN), 4.1 1.6 metastasis. rates 66.7% group-1 (0.1-0.5 ng/mL), 85.7% group-2 (0.5-1.0 100% group-3 (above 1.0 ng/mL). Among PET-positive (n = 26), 57.7% (15/26), LN 42.3% (11/26), metastasis 15.4% (4/26). In 53% (8/15) who focal uptake adjacent bladder PET. This suggested significant advantage having physiological urine excretion.[18F]PSMA-1007 showed high rate metastatic lesions. BCR, led suitable treatment strategies, such salvage surgical removal nodes.(UMIN Clinical Trials Registry) UMIN000037697.